A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
NCT ID: NCT00000824
Last Updated: 2016-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
INTERVENTIONAL
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
NCT00001064
Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
NCT00000756
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
NCT00833781
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
NCT00000875
A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
NCT00000852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dendritic cells and lymphocytes are obtained from an HIV-negative sibling. HIV-specific CTLs are generated from these cells and then infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lymphocytes, Activated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HLA A2+.
* Other HLA matching with sibling.
* CD4 count 100-350 cells/mm3.
* No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma).
* Current stable antiviral regimen.
* Normal lab values and chest x-ray.
Donor siblings must have:
* HLA A2+.
* HIV negativity.
* Good venous access.
* Ability to donate on multiple occasions.
* Negative status for hepatitis B and C.
Exclusion Criteria
Excluded:
* Immunomodulators.
* Cytokines.
* Systemic steroids.
* IV pentamidine.
* Investigational drugs.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Univ School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPIRAT 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.